Skip to content

EyePoint, Inc. EYPT Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
PVL
Palvella TherapeuticsPVLA
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's accrued expenses and other liabilities?
EyePoint, Inc. (EYPT) reported accrued expenses and other liabilities of $571K in Q1 2026.
How has EyePoint, Inc. 's accrued expenses and other liabilities changed year-over-year?
EyePoint, Inc. 's accrued expenses and other liabilities decreased by 88.5% year-over-year, from $4.97M to $571K.
What is the long-term trend for EyePoint, Inc. 's accrued expenses and other liabilities?
Over 4 years (2021 to 2025), EyePoint, Inc. 's accrued expenses and other liabilities has grown at a 2.4% compound annual growth rate (CAGR), from $8.48M to $9.32M.